



## **AgiOS Pharmaceuticals Added to Russell 2000®, 3000® and Global Indexes**

October 1, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 1, 2013-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that the company has been added to the Russell 2000®, Russell 3000® and Russell Global® Indexes as part of Russell Investments' third-quarter IPO additions that took place after market close on September 30, 2013.

The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000®, representing approximately 10 percent of the total market capitalization of that index. Membership in the Russell 2000® Index includes automatic inclusion in the appropriate growth and style indexes.

Russell indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Russell Investments determines membership for each index based on objective market capitalization rankings and style attributes. More than \$3.9 trillion in assets are currently benchmarked to the Russell family of indexes.

### **About Agios Pharmaceuticals, Inc.**

AgiOS Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and rare metabolic genetic diseases (known as inborn errors of metabolism or IEMs) through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and preclinical development. All Agios programs focus on genetically identified patient populations leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at [www.agios.com](http://www.agios.com).

### **Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "believe," "expect" "could," "should," "will," "may" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to important risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs, including the risks described under the caption "Risk Factors" in Agios' Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 which is on file with the Securities and Exchange Commission (SEC), and other filings that Agios may make with the SEC in the future, and other filings that Agios may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Agios Pharmaceuticals, Inc.

### **For Agios Pharmaceuticals, Inc.**

#### **Media Contact:**

Dan Budwick, 973-271-6085

[dan@purecommunicationsinc.com](mailto:dan@purecommunicationsinc.com)

or

#### **Investor Contact:**

Glenn Goddard

[investors@agios.com](mailto:investors@agios.com)